Arcellx reports 2022 results; announces Kite collaboration for CART-ddBCMA with $325M upfront

Arcellx, Inc.

Strategic collaboration with Kite (Gilead): $225M upfront + $100M equity; co-commercialize in US, royalties ex-US.
Phase 1 expansion data: 100% ORR, 71% CR/sCR in evaluable rrMM patients; no delayed neurotoxicity.
Pivotal iMMagine-1 trial dosed; Phase 1 ACLX-002 for AML/MDS initiated.
Cash $254.8M at Dec 31, 2022; plus $325M from Kite/Gilead in Jan 2023; expected to fund through BLA filing H1 2025.
Net loss $188.7M for FY2022 vs $65.0M in 2021; R&D expenses $149.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcellx, Inc. reported fourth quarter and year ended December 31, 2022 results: net income Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188..

Period: fourth quarter and year ended December 31, 2022
Net income: Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188.
Result: reported results

Exact text from the filing

Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.